Alnylam Pharmaceuticals, Inc. (ALNY)
266.11
+1.61
(+0.61%)
USD |
NASDAQ |
Sep 04, 16:00
267.00
+0.89
(+0.33%)
After-Hours: 20:00
Alnylam Pharmaceuticals Research and Development Expense (Quarterly) : 413.13M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 413.13M |
| March 31, 2026 | 364.87M |
| December 31, 2025 | 372.22M |
| September 30, 2025 | 358.81M |
| June 30, 2025 | 323.62M |
| March 31, 2025 | 265.12M |
| December 31, 2024 | 300.17M |
| September 30, 2024 | 270.93M |
| June 30, 2024 | 294.14M |
| March 31, 2024 | 261.00M |
| December 31, 2023 | 272.14M |
| September 30, 2023 | 253.18M |
| June 30, 2023 | 248.53M |
| March 31, 2023 | 230.57M |
| December 31, 2022 | 262.04M |
| September 30, 2022 | 245.37M |
| June 30, 2022 | 205.71M |
| March 31, 2022 | 169.89M |
| December 31, 2021 | 229.05M |
| September 30, 2021 | 194.57M |
| June 30, 2021 | 182.64M |
| March 31, 2021 | 185.90M |
| December 31, 2020 | 168.47M |
| September 30, 2020 | 161.78M |
| June 30, 2020 | 155.00M |
| Date | Value |
|---|---|
| March 31, 2020 | 169.57M |
| December 31, 2019 | 201.30M |
| September 30, 2019 | 160.80M |
| June 30, 2019 | 163.89M |
| March 31, 2019 | 129.13M |
| December 31, 2018 | 131.04M |
| September 30, 2018 | 139.94M |
| June 30, 2018 | 137.58M |
| March 31, 2018 | 96.86M |
| December 31, 2017 | 117.77M |
| September 30, 2017 | 95.25M |
| June 30, 2017 | 90.63M |
| March 31, 2017 | 86.98M |
| December 31, 2016 | 105.01M |
| September 30, 2016 | 97.94M |
| June 30, 2016 | 83.17M |
| March 31, 2016 | 96.27M |
| December 31, 2015 | 82.84M |
| September 30, 2015 | 68.62M |
| June 30, 2015 | 67.01M |
| March 31, 2015 | 58.04M |
| December 31, 2014 | 55.55M |
| September 30, 2014 | 46.27M |
| June 30, 2014 | 44.67M |
| March 31, 2014 | 43.76M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Ionis Pharmaceuticals, Inc. | 216.41M |
| BridgeBio Pharma, Inc. | 149.45M |
| Regeneron Pharmaceuticals, Inc. | 1.508B |
| Vertex Pharmaceuticals, Inc. | 993.80M |
| Pfizer Inc. | 2.746B |